Sign in
Active, not recruitingPhase 2

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

Key facts

Who runs it
BeOne Medicines
Where
Baltimore, Boston, Charlotte, Columbus, Dallas, Denver, Duarte, Hattiesburg, Miami, New York, Richmond, Rochester, Salt Lake City, Seattle, Warrenville, Washington D.C., and Waukee, United StatesSee the 17 sitesAlso in 8 other countries, 50 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
114 people enrolled
Started
23 Oct 2023
Expected to end
Aug 2028
Type of study
Interventional, 4 groups
Treatments tested
  • Sonrotoclax
  • Zanubrutinib
Record updated
20 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Clinical and definitive histologic diagnosis of WM
  • Meeting ≥ 1 criterion for treatment according to consensus panel criteria from the 2nd International Workshop on Waldenström's Macroglobulinemia (IWWM)
  • For Cohorts 1-3, refractory or relapsed disease at study entry unless participants had intolerance to the most recent therapy. Refractory disease is defined as not attaining at least a major response, or progressing while on or within 6 months of completing therapy. Relapsed disease is defined as attaining at least a major response to therapy and meeting the criteria for disease progression beyond 6 months after completing therapy
  • For Cohort 4, patients must not have received prior therapy for WM (except for plasmapheresis)
  • Adequate organ function

Who cannot take part

  • Uncontrolled active systemic infection or recent infection requiring parenteral antimicrobial therapy that was completed ≤ 14 days before the first dose of the study drug; Note: Other protocol defined Inclusion/Exclusion criteria may apply
  • History of other malignancies ≤ 2 years before study entry
  • Central nervous system (CNS) involvement by WM
  • Transformation to aggressive lymphoma, such as diffuse large B-cell lymphoma

Where in United States

Also in 8 other countries, 50 sites

  • University of Maryland Greenebaum Comprehensive Cancer CenterBaltimore, United States
  • Dana-Farber Cancer InstituteBoston, United States
  • Atrium Health Levine Cancer Institute (Lci)Charlotte, United States
  • Ohio State University Comprehensive Cancer CenterColumbus, United States
  • UT Southwestern Medical CenterDallas, United States
  • Colorado Blood Cancer InstituteDenver, United States
  • City of Hope National Medical CenterDuarte, United States
  • Hattiesburg Hematology and Oncology ClinicHattiesburg, United States
  • University of MiamiMiami, United States
  • Memorial Sloan Kettering Cancer Center MskccNew York, United States
  • Virginia Commonwealth University/Massey Cancer CenterRichmond, United States
  • Mayo Clinic - RochesterRochester, United States
  • Huntsman Cancer InstituteSalt Lake City, United States
  • University of WashingtonSeattle, United States
  • Northwestern Medicine Cancer CenterWarrenville, United States
  • MedStar Georgetown University HospitalWashington D.C., United States
  • Mission Cancer and BloodWaukee, United States

About the trial

What the trial wants to find out

This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.

The 4 groups in the trial

  • Cohort 1Treatment being tested

    Participants with R/R disease to both Bruton tyrosine kinase (BTK) inhibitor and anti-CD20 antibody-based systemic therapy containing chemotherapy or proteasome inhibitor will receive sonrotoclax at a standard dose, given orally once daily.

    Treatment: Sonrotoclax

  • Cohort 2Treatment being tested

    Participants with R/R disease to anti-CD20 antibody-based systemic therapy containing chemotherapy or proteasome inhibitor and were intolerant to BTK inhibitor will receive sonrotoclax at a standard dose, given orally once daily.

    Treatment: Sonrotoclax

  • Cohort 3Treatment being tested

    Participants with R/R disease to a BTK inhibitor treatment and are unsuitable for chemoimmunotherapy will receive sonrotoclax at a standard dose, given orally once daily.

    Treatment: Sonrotoclax

  • Cohort 4Treatment being tested

    Participants with previously untreated WM will receive sonrotoclax and zanubrutinib combination therapy for a fixed duration.

    Treatment: Sonrotoclax and Zanubrutinib

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
Record updated
20 October 2026